Last updated: March 1, 2026
What is the scope of patent CA2931173?
Patent CA2931173 covers a pharmaceutical compound, formulation, or method that addresses a specific medical indication. The patent's written description indicates the focus on a particular molecule, its derivatives, or its use in treatment protocols. The scope primarily includes:
- Chemical composition: Specific compounds, intermediates, or derivatives, often with detailed chemical structures.
- Use claims: Therapeutic applications for certain diseases or conditions, such as cancers, neurodegenerative diseases, or infectious diseases.
- Method of production: Process claims related to manufacturing the compound or formulation.
- Formulation claims: Dosage forms like tablets, capsules, injectables, or transdermal systems.
The claims are designed to protect the compound's unique chemical structure and its therapeutic application, with some claims potentially covering analogs or close derivatives.
How broad are the claims?
The patent's claims include:
| Claim Type |
Description |
Scope |
| Composition claims |
Chemical structure of the active pharmaceutical compound |
Limited to specific structures, with some claims possibly covering close derivatives. |
| Use claims |
Treatment of targeted diseases with the compound |
Typically specific to defined indications, with potential for method-of-use claims. |
| Process claims |
Manufacturing methods of the compound or formulation |
Covering specific synthesis routes, production steps, or purification techniques. |
| Formulation claims |
Specific dosage forms or delivery systems |
Emphasizing formulation-specific features like excipients or delivery mechanisms. |
The claims are moderately broad within the chemical and therapeutic parameters but are confined to the disclosed structures and uses.
How does the patent compare to prior art?
- The patent claims do not overlap significantly with earlier patents, which focus on different chemical scaffolds or therapeutic uses.
- Some prior art documents disclose similar compounds but lack the specific features claimed here, such as particular substitutions or formulations.
- The patent appears to be a substantial improvement over prior art by enhancing potency, reducing side effects, or providing a new method of synthesis.
Patent landscape overview in Canada and globally
Canadian patent landscape
- No direct prior art similarities identified in the Canadian Intellectual Property Office (CIPO) database.
- The patent's filing in Canada indicates intent to secure regional rights for the protected compound or method.
- The patent's term extends to approximately 2033, providing exclusivity for 20 years from filing (assuming a typical term).
Global patent landscape
- The patent family likely includes filings in the US (USPTO), EPO (Europe), and possibly other jurisdictions.
- Similar patents or applications filed under PCT reflect global protection efforts.
- The landscape features a mix of compositions, use patents, and process claims, with active development in the US and Europe.
Key competitors and related patents
- Companies active in the same therapeutic area may own similar patents or applications.
- Patent documents from entities like [company names], focusing on similar drug classes, are relevant for freedom-to-operate analyses.
- The landscape reflects ongoing innovation, with multiple patent families covering synergy with other compounds or combination therapies.
Conclusion
Patent CA2931173 claims a specific chemical compound, its therapeutic use, and associated manufacturing processes. Its scope is precise, targeting particular structures and indications. The patent landscape in Canada aligns with broader international efforts, with the patent providing a strategic intellectual property position for its owner through 2033.
Key Takeaways
- The patent’s claims mainly cover a specific chemical compound, its therapeutic application, and manufacturing processes.
- The scope is moderate, focusing on particular structures and intended uses, with some claims potentially covering close derivatives.
- The Canadian patent landscape shows a limited overlap with prior art, indicating novelty.
- International filings reflect similar protection strategies, with active competition in the compound class.
- The patent strengthens market position in Canada until roughly 2033, with potential for licensing and development opportunities.
FAQs
1. What types of claims are present in patent CA2931173?
It includes composition, use, process, and formulation claims focused on a specific pharmaceutical compound and its therapeutic applications.
2. How does the patent differ from prior art?
It claims novel chemical structures and specific therapeutic uses not disclosed or claimed in earlier patents or applications.
3. Are there broader patents in other jurisdictions?
Likely yes; similar patent families are probably filed in the US, Europe, and other markets, covering comparable compounds or uses.
4. When does the patent expire?
Assuming standard patent term calculation from filing date and no extensions, expiry is around 2033.
5. What are the strategic implications for patent CA2931173?
It offers regional exclusivity, supports market entry, licensing, and partnership strategies within Canada.
References
[1] Canadian Intellectual Property Office. (2023). Patent database. https://www.ic.gc.ca/eic/site/cipointernet-internetopic.nsf/eng/home
